Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy

NCT00435487 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00435487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00435487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Terminated
Start date
June 30, 2007
Completion date
December 31, 2008
Enrollment
173 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

angina, unstable, myocardial infarction